Press OW et al. A Phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs CHOP chemotherapy plus iodine-131-tositumomab for the treatment of newly diagnosed follicular non-Hodgkin’s lymphoma. Proc ASH 2011;Abstract 98.

Illidge TM et al. Fractionated ⁹⁰Y ibritumomab tiuxetan (Zevalin^TM) radioimmunotherapy as an initial therapy of follicular lymphoma — First results from a Phase II study in patients requiring treatment according to GELF/BNLI criteria. Proc ASH 2011;Abstract 102.

Dr Gregory is the Elodia Kehm Chair of Hematology, Professor of Medicine and Director of the Hematology Section at Rush University Medical Center in Chicago, Illinois.

Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.